Free Trial

Rocket Pharmaceuticals (RCKT) Competitors

Rocket Pharmaceuticals logo
$2.88 +0.29 (+11.20%)
Closing price 04:00 PM Eastern
Extended Trading
$2.88 0.00 (-0.17%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

RCKT vs. CRMD, NAGE, WVE, AUPH, ELVN, ABCL, PAHC, VERV, COLL, and NTLA

Should you be buying Rocket Pharmaceuticals stock or one of its competitors? The main competitors of Rocket Pharmaceuticals include CorMedix (CRMD), Niagen Bioscience (NAGE), WAVE Life Sciences (WVE), Aurinia Pharmaceuticals (AUPH), Enliven Therapeutics (ELVN), AbCellera Biologics (ABCL), Phibro Animal Health (PAHC), Verve Therapeutics (VERV), Collegium Pharmaceutical (COLL), and Intellia Therapeutics (NTLA). These companies are all part of the "pharmaceutical products" industry.

Rocket Pharmaceuticals vs. Its Competitors

Rocket Pharmaceuticals (NASDAQ:RCKT) and CorMedix (NASDAQ:CRMD) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, earnings, analyst recommendations, valuation and risk.

98.4% of Rocket Pharmaceuticals shares are owned by institutional investors. Comparatively, 34.2% of CorMedix shares are owned by institutional investors. 24.8% of Rocket Pharmaceuticals shares are owned by company insiders. Comparatively, 5.3% of CorMedix shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Rocket Pharmaceuticals had 23 more articles in the media than CorMedix. MarketBeat recorded 51 mentions for Rocket Pharmaceuticals and 28 mentions for CorMedix. CorMedix's average media sentiment score of 0.52 beat Rocket Pharmaceuticals' score of 0.03 indicating that CorMedix is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Rocket Pharmaceuticals
5 Very Positive mention(s)
2 Positive mention(s)
39 Neutral mention(s)
1 Negative mention(s)
4 Very Negative mention(s)
Neutral
CorMedix
7 Very Positive mention(s)
3 Positive mention(s)
11 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Rocket Pharmaceuticals presently has a consensus price target of $18.60, indicating a potential upside of 545.83%. CorMedix has a consensus price target of $17.14, indicating a potential upside of 47.91%. Given Rocket Pharmaceuticals' higher possible upside, equities research analysts clearly believe Rocket Pharmaceuticals is more favorable than CorMedix.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Rocket Pharmaceuticals
1 Sell rating(s)
8 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.41
CorMedix
0 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.88

CorMedix has higher revenue and earnings than Rocket Pharmaceuticals. Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rocket PharmaceuticalsN/AN/A-$258.75M-$2.63-1.10
CorMedix$43.47M18.08-$17.93M$0.2252.68

Rocket Pharmaceuticals has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500. Comparatively, CorMedix has a beta of 1.58, suggesting that its share price is 58% more volatile than the S&P 500.

CorMedix has a net margin of 20.81% compared to Rocket Pharmaceuticals' net margin of 0.00%. CorMedix's return on equity of 22.57% beat Rocket Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Rocket PharmaceuticalsN/A -64.92% -56.13%
CorMedix 20.81%22.57%17.02%

Summary

CorMedix beats Rocket Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

Get Rocket Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for RCKT and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RCKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RCKT vs. The Competition

MetricRocket PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$276.58M$2.88B$5.54B$8.87B
Dividend YieldN/A2.64%5.39%4.10%
P/E Ratio-1.1021.3126.1719.90
Price / SalesN/A278.47414.67113.66
Price / CashN/A41.4736.1356.90
Price / Book0.577.518.055.38
Net Income-$258.75M-$55.05M$3.15B$248.50M
7 Day Performance8.68%2.45%1.85%2.97%
1 Month Performance3.97%7.33%4.81%6.02%
1 Year Performance-85.44%5.38%34.86%20.39%

Rocket Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RCKT
Rocket Pharmaceuticals
4.9137 of 5 stars
$2.88
+11.2%
$18.60
+545.8%
-87.5%$276.58MN/A-1.10240Trending News
High Trading Volume
CRMD
CorMedix
2.3588 of 5 stars
$16.56
+21.7%
$15.83
-4.4%
+175.5%$1.12B$43.47M75.2830Analyst Forecast
Analyst Revision
High Trading Volume
NAGE
Niagen Bioscience
1.4985 of 5 stars
$13.64
+1.5%
$19.50
+43.0%
N/A$1.07B$99.60M80.24120
WVE
WAVE Life Sciences
4.5404 of 5 stars
$6.96
+5.9%
$20.50
+194.5%
+24.4%$1.07B$108.30M-8.29240Positive News
AUPH
Aurinia Pharmaceuticals
2.7144 of 5 stars
$7.83
+0.8%
$11.50
+46.9%
+36.2%$1.06B$235.13M27.96300
ELVN
Enliven Therapeutics
2.4691 of 5 stars
$20.29
-4.7%
$39.60
+95.2%
-13.4%$995.61MN/A-10.5750Analyst Forecast
High Trading Volume
ABCL
AbCellera Biologics
2.2401 of 5 stars
$3.33
-2.3%
$8.33
+150.3%
+25.5%$993.75M$23.11M-5.95500
PAHC
Phibro Animal Health
3.5669 of 5 stars
$24.46
+2.4%
$20.80
-15.0%
+56.2%$991.36M$1.02B31.361,940
VERV
Verve Therapeutics
3.5023 of 5 stars
$11.11
+0.5%
$14.75
+32.8%
+126.5%$990.35M$32.33M-5.27110High Trading Volume
COLL
Collegium Pharmaceutical
4.0327 of 5 stars
$29.88
+0.2%
$43.75
+46.4%
-7.1%$960.10M$664.28M24.49210News Coverage
NTLA
Intellia Therapeutics
4.6699 of 5 stars
$9.23
+0.3%
$34.95
+278.7%
-56.0%$956.04M$57.88M-1.76600

Related Companies and Tools


This page (NASDAQ:RCKT) was last updated on 7/2/2025 by MarketBeat.com Staff
From Our Partners